Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across ...
At four-years-old, William Moore’s muscles are already beginning to deteriorate. Something as small as a slight gust of wind and sometimes even just thin air is enough to knock William over. Diagnosed ...
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...
2d
State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...
The most important therapy in Sarepta Therapeutics' portfolio is Elevidys, which last year earned full FDA approval for use in ambulatory Duchenne muscular dystrophy patients. The medicine also ...
Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...
Elevidys (delandistrogene moxeparvovec) can now be used to treat both ambulatory and non-ambulatory boys aged four and above with DMD, a major expansion on its earlier accelerated approval with a ...
The result comes a few months after the only FDA-approved gene therapy for DMD – Roche/Sarepta’s Elevidys (delandistrogene moxeparvovec) – failed to meet its primary objective in a phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback